- Record: found
- Abstract: found
- Article: not found
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To investigate the impact of the uncertainty stemming from products with European conditional marketing authorization (CMA) or authorization in exceptional circumstances (AEC) on the National Institute for Health and Care Excellence's (NICE) recommendations.